EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (AMEX:AIS) announced that data from two clinical trials for ANTUROL™, its transdermal oxybutynin ATD™ gel, will be presented at the 28th Annual Scientific Meeting of the American Urogynecologic Society (AUGS) on September 27-29, 2007, in Hollywood FL. Oxybutynin is considered the gold standard for Overactive Bladder treatment, and is currently available only in oral dose and adhesive patch formulations.
